Literature DB >> 25664138

Autoimmune thrombocytopenia: a complication of fludarabine therapy in the treatment of Waldenstrom's macroglobulinemia.

Yujie Jiang1, Hongjuan Peng2, Xin Cui1, Ying Zhou3, Dai Yuan1, Xiaohui Sui1, Lingyan Zhang1, Hongzhi Xu1.   

Abstract

Fludarabine is an effective purine analogue which has become extensive used in lymph proliferative malignancies. However, an increased incidence of autoimmune disorders including autoimmune hemolytic anemia (AHIA) and idiopathic thrombocytopenia (ITP) is reported with the use of fludarabine. The exact mechanism for fludarabine to exacerbate thrombocytopenia is not distinct. In our report, we describe a patient with WM developed a refractory, life-threatening and fludarabine-associated thrombocytopenia which could not be explained by the cytotoxic effects of fludarabine. Possible mechanisms of fludarabine on autoimmune disorders are discussed.

Entities:  

Keywords:  Fludarabine; Waldenstrom’s macroglobulinemia; thrombocytopenia

Year:  2014        PMID: 25664138      PMCID: PMC4307585     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders.

Authors:  M Leach; R M Parsons; J T Reilly; D A Winfield
Journal:  Clin Lab Haematol       Date:  2000-06

Review 2.  B-cell chronic lymphocytic leukemia: a bird of a different feather.

Authors:  F Caligaris-Cappio; T J Hamblin
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

3.  Evans syndrome complicating fludarabine treatment for advanced B-CLL.

Authors:  L Shvidel; M Shtarlid; A Klepfish; E Sigler; A Berrebi
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

Review 4.  An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL.

Authors:  G Dighiero
Journal:  Nouv Rev Fr Hematol       Date:  1988

5.  Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia.

Authors:  Katsumichi Fujimaki; Hirotaka Takasaki; Hideyuki Koharazawa; Maki Takabayashi; Satoshi Yamaji; Yasuhisa Baba; Heiwa Kanamori; Yoshiaki Ishigatsubo
Journal:  Leuk Lymphoma       Date:  2005-07

6.  X-radiation and alkylating agents as possible "trigger" mechanisms in the autoimmune complications of malignant lymphophroliferative disease.

Authors:  F B Lewis; R S Schwartz; W Dameshek
Journal:  Clin Exp Immunol       Date:  1966-01       Impact factor: 4.330

7.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

Review 8.  Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.

Authors:  Michael Hallek
Journal:  Am J Hematol       Date:  2013-09       Impact factor: 10.047

9.  Rituximab for the treatment of acute refractory ITP.

Authors:  Sei-Gyung Kim; Donna Whyte; Farzana D Pashankar
Journal:  J Pediatr Hematol Oncol       Date:  2014-04       Impact factor: 1.289

Review 10.  Fludarabine: a review of the clear benefits and potential harms.

Authors:  Joshua Lukenbill; Matt Kalaycio
Journal:  Leuk Res       Date:  2013-06-17       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.